FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2756156907> ?p ?o ?g. }

• W2756156907 endingPage "77859" @default.
• W2756156907 startingPage "77846" @default.
• W2756156907 abstract "// Jonathan Cole 1 , Marie-Christine Guiot 2 , Michel Gravel 1 , Cynthia Bernier 1 , Gordon C. Shore 1 and Anne Roulston 1 1 Laboratory for Therapeutic Development, Rosalind and Morris Goodman Cancer Research Centre, and Department Biochemistry, McGill University, Montreal, QC, Canada 2 Department of Pathology, Montreal Neurological Hospital, Montreal, QC, Canada Correspondence to: Anne Roulston, email: Anne.roulston@mcgill.ca Keywords: NAMPT, NAPRT, biomarker, NAMPT inhibitor, NAD + biosynthesis Received: April 12, 2017     Accepted: August 17, 2017     Published: September 12, 2017 ABSTRACT Tumor cells are particularly dependent on NAD + due to higher rates of metabolism, DNA synthesis and repair. Nicotinamide phosphoribosyltransferase inhibitors (NAMPTis) inhibit NAD + biosynthesis and represent promising new anti-cancer agents. However, clinical efficacy has been limited by toxicities demonstrating the need for drug combinations to broaden the therapeutic index. One potential combination involves niacin/NAMPTi co-administration. Niacin can rescue NAD + biosynthesis through a parallel pathway that depends on nicotinic acid phosphoribosyltransferase (NAPRT) expression. Most normal tissues express NAPRT while a significant proportion of malignant cells do not, providing a possible selection marker for patients to achieve NAMPTi efficacy while minimizing toxicities. Here we identify and validate a novel highly NAPRT-specific monoclonal antibody (3C6D2) that detects functional NAPRT in paraffin embedded tissue sections by immunohistochemistry (IHC). NAPRT detection by 3C6D2 coincides with the ability of niacin to rescue cells from NAMPTi induced cytotoxicity in cell lines and animal xenograft models. 3C6D2 binds to an epitope that is unique to NAPRT among phosphoribosyltransferases. In a series of primary tumor samples from lung and brain cancer patients, we demonstrate that >70 % of human small cell lung carcinomas, glioblastomas and oligodendrogliomas lack NAPRT identifying them as potentially suitable indications for the NAMPT/niacin combination." @default.
• W2756156907 created "2017-09-25" @default.
• W2756156907 creator A5006248707 @default.
• W2756156907 creator A5010527031 @default.
• W2756156907 creator A5052520192 @default.
• W2756156907 creator A5056470194 @default.
• W2756156907 creator A5064465419 @default.
• W2756156907 creator A5081475158 @default.
• W2756156907 date "2017-09-12" @default.
• W2756156907 modified "2023-09-27" @default.
• W2756156907 title "Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy" @default.
• W2756156907 cites W1497983863 @default.
• W2756156907 cites W1606706474 @default.
• W2756156907 cites W1788843509 @default.
• W2756156907 cites W1858293449 @default.
• W2756156907 cites W1953904757 @default.
• W2756156907 cites W1974869964 @default.
• W2756156907 cites W1981575339 @default.
• W2756156907 cites W1986553481 @default.
• W2756156907 cites W1988004867 @default.
• W2756156907 cites W1995766860 @default.
• W2756156907 cites W1999564272 @default.
• W2756156907 cites W2012034410 @default.
• W2756156907 cites W2012538520 @default.
• W2756156907 cites W2014150894 @default.
• W2756156907 cites W2019581322 @default.
• W2756156907 cites W2026814500 @default.
• W2756156907 cites W2031050244 @default.
• W2756156907 cites W2053682896 @default.
• W2756156907 cites W2080595001 @default.
• W2756156907 cites W2083287520 @default.
• W2756156907 cites W2095406887 @default.
• W2756156907 cites W2099580944 @default.
• W2756156907 cites W2119700304 @default.
• W2756156907 cites W2125997801 @default.
• W2756156907 cites W2134126680 @default.
• W2756156907 cites W2139320630 @default.
• W2756156907 cites W2155867477 @default.
• W2756156907 cites W2163366731 @default.
• W2756156907 cites W2167402014 @default.
• W2756156907 cites W2192221936 @default.
• W2756156907 cites W2195577082 @default.
• W2756156907 cites W2235472906 @default.
• W2756156907 cites W2280782183 @default.
• W2756156907 cites W2546991359 @default.
• W2756156907 doi "https://doi.org/10.18632/oncotarget.20840" @default.
• W2756156907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5652819" @default.
• W2756156907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29100430" @default.
• W2756156907 hasPublicationYear "2017" @default.
• W2756156907 type Work @default.
• W2756156907 sameAs 2756156907 @default.
• W2756156907 citedByCount "13" @default.
• W2756156907 countsByYear W27561569072018 @default.
• W2756156907 countsByYear W27561569072019 @default.
• W2756156907 countsByYear W27561569072020 @default.
• W2756156907 countsByYear W27561569072021 @default.
• W2756156907 countsByYear W27561569072022 @default.
• W2756156907 crossrefType "journal-article" @default.
• W2756156907 hasAuthorship W2756156907A5006248707 @default.
• W2756156907 hasAuthorship W2756156907A5010527031 @default.
• W2756156907 hasAuthorship W2756156907A5052520192 @default.
• W2756156907 hasAuthorship W2756156907A5056470194 @default.
• W2756156907 hasAuthorship W2756156907A5064465419 @default.
• W2756156907 hasAuthorship W2756156907A5081475158 @default.
• W2756156907 hasBestOaLocation W27561569071 @default.
• W2756156907 hasConcept C121608353 @default.
• W2756156907 hasConcept C126322002 @default.
• W2756156907 hasConcept C181199279 @default.
• W2756156907 hasConcept C2779728014 @default.
• W2756156907 hasConcept C2780092750 @default.
• W2756156907 hasConcept C2780391879 @default.
• W2756156907 hasConcept C502942594 @default.
• W2756156907 hasConcept C55493867 @default.
• W2756156907 hasConcept C71924100 @default.
• W2756156907 hasConcept C75520062 @default.
• W2756156907 hasConcept C86803240 @default.
• W2756156907 hasConcept C98274493 @default.
• W2756156907 hasConceptScore W2756156907C121608353 @default.
• W2756156907 hasConceptScore W2756156907C126322002 @default.
• W2756156907 hasConceptScore W2756156907C181199279 @default.
• W2756156907 hasConceptScore W2756156907C2779728014 @default.
• W2756156907 hasConceptScore W2756156907C2780092750 @default.
• W2756156907 hasConceptScore W2756156907C2780391879 @default.
• W2756156907 hasConceptScore W2756156907C502942594 @default.
• W2756156907 hasConceptScore W2756156907C55493867 @default.
• W2756156907 hasConceptScore W2756156907C71924100 @default.
• W2756156907 hasConceptScore W2756156907C75520062 @default.
• W2756156907 hasConceptScore W2756156907C86803240 @default.
• W2756156907 hasConceptScore W2756156907C98274493 @default.
• W2756156907 hasIssue "44" @default.
• W2756156907 hasLocation W27561569071 @default.
• W2756156907 hasLocation W27561569072 @default.
• W2756156907 hasLocation W27561569073 @default.
• W2756156907 hasLocation W27561569074 @default.
• W2756156907 hasOpenAccess W2756156907 @default.
• W2756156907 hasPrimaryLocation W27561569071 @default.
• W2756156907 hasRelatedWork W1778984120 @default.
• W2756156907 hasRelatedWork W2041163347 @default.

• next